NLS Pharma Business

AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidaemia.

The two companies have expanded their partnership to accelerate the development of the Dispersome technology platform and further expand its applicability and reach for increasing the solubility and bioavailability of small drug molecules.

AstraZeneca’s supplemental New Drug Application (sNDA) for Calquence has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting based on the positive results from the DESTINY-Breast06 Phase III trial which compared Enhertu to chemotherapy.

The Board of Directors of Spago Nanomedical has decided that the company's resources will be focused on the development of Tumorad with the company's primary priority being the execution of the ongoing clinical study Tumorad-01 with the candidate drug 177Lu-SN201.

Vicore Pharma Holding has announced an investment from Sanofi in Vicore through a commitment to subscribe for shares in the ongoing rights issue corresponding to a total of approximately USD 10 million.